GoKawiilZach Reitano discusses scaling GLP-1 care, tackling backlash, and what comes after weight-loss drugs go mainstream. Since first appearing on the Masters of Scale podcast at the height of the Ozempic-Wegovy-Zepbound boom, Zach Reitano, CEO of Ro, has helped scale his company into a leading provider of branded GLP-1s—grabbing headlines with a 2026 Super Bowl ad featuring tennis champion Serena Williams and landing a major partnership with Novo Nordisk for the pill version of Wegovy. Now Reitano has new challenges to address: the long-term health unknowns of the medications, the cultural backlash to “Ozempic face,” and what this wave of disruption could mean not just for pharma but for the future of healthcare.
Ro CEO on the next phase of the Ozempic boom
Why This Matters
The article highlights the rapid growth and mainstream adoption of GLP-1 medications like Ozempic, driven by companies like Ro and major partnerships. This shift signifies a transformative moment in healthcare, influencing both pharmaceutical innovation and consumer access to weight-loss treatments. Addressing long-term health concerns and cultural perceptions will be crucial as these drugs become more integrated into standard care.
Key Takeaways
- Ro's strategic partnerships are accelerating GLP-1 adoption.
- Long-term health effects and cultural backlash pose challenges for widespread use.
- The mainstreaming of weight-loss drugs could reshape future healthcare models.
Get alerts for these topics